Literature DB >> 21539943

Conformational, receptor interaction and alanine scan studies of glucose-dependent insulinotropic polypeptide.

Kalyana C Venneti1, J Paul G Malthouse, Finbarr P M O'Harte, Chandralal M Hewage.   

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) is an insulinotropic incretin hormone that stimulates insulin secretion during a meal. GIP has glucose lowering abilities and hence is considered as a potential target molecule for type 2 diabetes therapy. In this article, we present the solution structure of GIP in membrane-mimicking environments by proton NMR spectroscopy and molecular modelling. GIP adopts an α-helical conformation between residues Phe(6)-Gly(31) and Ala(13)-Gln(29) for micellar and bicellar media, respectively. Previously we examined the effect of N-terminal Ala substitution in GIP, but here eight GIP analogues were synthesised by replacing individual residues within the central 8-18 region with alanine. These studies showed relatively minor changes in biological activity as assessed by insulin releasing potency. However, at higher concentration, GIP(Ala(16)), and GIP(Ala(18)) showed insulin secreting activity higher than the native GIP (P<0.01 to P<0.001) in cultured pancreatic BRIN-BD11 cells. Receptor interaction studies of the native GIP with the extracellular domain of its receptor were performed by using two different docking algorithms. At the optimised docking conformation, the complex was stabilised by the presence of hydrophobic interactions and intermolecular hydrogen bonding. Further, we have identified some potentially important additional C-terminal interactions of GIP with its N-terminal extracellular receptor domain. 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21539943     DOI: 10.1016/j.bbapap.2011.04.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection.

Authors:  Peter Lindquist; Lærke Smidt Gasbjerg; Jacek Mokrosinski; Jens Juul Holst; Alexander Sebastian Hauser; Mette Marie Rosenkilde
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

Review 2.  Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP.

Authors:  Lijing Wang
Journal:  Drug Des Devel Ther       Date:  2022-05-25       Impact factor: 4.319

3.  A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents.

Authors:  K Tatarkiewicz; D M Hargrove; C M Jodka; B R Gedulin; P A Smith; J A Hoyt; A Lwin; L Collins; L Mamedova; O E Levy; L D'Souza; S Janssen; V Srivastava; S S Ghosh; D G Parkes
Journal:  Diabetes Obes Metab       Date:  2013-08-19       Impact factor: 6.577

4.  Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors.

Authors:  A H Sparre-Ulrich; L S Hansen; B Svendsen; M Christensen; F K Knop; B Hartmann; J J Holst; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2015-11-20       Impact factor: 8.739

5.  Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor.

Authors:  Jennifer D Könitzer; Shreya Pramanick; Qi Pan; Robert Augustin; Sebastian Bandholtz; William Harriman; Shelley Izquierdo
Journal:  MAbs       Date:  2017-01-05       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.